

Opportunity Title: FDA T Cell Studies on the Ebola Virus Glycoprotein

Opportunity Reference Code: FDA-CBER-2019-0037

Organization U.S. Food and Drug Administration (FDA)

Reference Code FDA-CBER-2019-0037

How to Apply A complete application consists of:

- An application
- Transcripts – [Click here for detailed information about acceptable transcripts](#)
- A current resume/CV, including academic history, employment history, relevant experiences, and publication list
- One educational or professional recommendation. Your application will be considered incomplete, and will not be reviewed until one recommendation is submitted.

All documents must be in English or include an official English translation.

If you have questions, send an email to ORISE.FDA.CBER@orau.org. Please include the reference code for this opportunity in your email.

Application Deadline 9/10/2019 3:00:00 PM Eastern Time Zone

Description *Applications will be reviewed on a rolling-basis.


A research opportunity is available in the Division of Viral Products (DVP), Office of Vaccines Research and Review (OVRR), at the Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA) in Silver Spring, Maryland.

There is a great deal of emphasis on the development of vaccines against Ebola virus (EBOV). Understanding EBOV T cell phenotypes induced following vaccination with recombinant proteins or viral expression vectors is critical to assessing the potential success of vaccine candidates in a clinical setting. This project involves the immunization of mice with candidate vaccines and the analysis of EBOV-specific T-cells in vitro. This project does not involve the use or handling of live Ebola virus.

The selected participant will be involved in a research project that was designed to better understand EBOV-specific T-cell immune responses to vaccines. This is a unique research project in basic science that is hypothesis-driven and involves immunization of mice and analysis of T-cell phenotypes and frequencies. The research training will provide the participant with experience in handling high profile vaccine candidates that are important to the US public health. The learning objective of this appointment are: cell culture, virus titration, mouse inoculation, tissue extraction, T-cell analysis, neutralization assays and quantification of RNA in cells and tissue.


This program, administered by ORAU through its contract with the U.S. Department of Energy to manage the Oak Ridge Institute for Science and Education, was established through an interagency agreement between DOE and FDA. The initial appointment is for one year, but may be renewed upon recommendation of FDA contingent on the availability of funds. The participant will receive a monthly stipend commensurate with educational level and experience. Proof of health insurance is required for participation in this program. The appointment is full-time at FDA in the Silver Spring, Maryland, area. Participants do not become employees of FDA, DOE or the program administrator, and there are no employment-related benefits.


Completion of a successful background investigation by the Office of Personnel Management is required for an applicant to be on-boarded at FDA. OPM can complete a background investigation only for individuals, including non-US Citizens, who have resided in the US for a total of three of




ORISE GO

The ORISE GO mobile app helps you stay engaged, connected and informed during your ORISE experience – from application, to offer, through your appointment and even as an ORISE alum!

Visit ORISE GO 

GET IT ON
 **Google Play**

Download on the
 **App Store**

Opportunity Title: FDA T Cell Studies on the Ebola Virus Glycoprotein

Opportunity Reference Code: FDA-CBER-2019-0037

the past five years.

FDA requires ORISE participants to read and sign their FDA Education and Training Agreement within 30 days of his/her start date, setting forth the conditions and expectations for his/her educational appointment at the agency. This agreement covers such topics as the following:


- Non-employee nature of the ORISE appointment;
- Prohibition on ORISE Fellows performing inherently governmental functions;
- Obligation of ORISE Fellows to convey all necessary rights to the FDA regarding intellectual property conceived or first reduced to practice during their fellowship;
- The fact that research materials and laboratory notebooks are the property of the FDA;
- ORISE fellow's obligation to protect and not to further disclose or use non-public information.

Qualifications The qualified candidate should have received a bachelor's degree in one of the relevant fields, or be currently pursuing the degree and will reach completion by July 2019. Degree must have been received within five years of the appointment start date.

Preferred skills:

- Previous experience with cells and aseptic technique
- Experience with PCR
- Basic knowledge of molecular biology and cloning

Eligibility Requirements

- **Degree:** Bachelor's Degree received within the last 60 months or anticipated to be received by 7/31/2019 11:59:00 PM.
- **Discipline(s):**
 - **Life Health and Medical Sciences** ([8](#) )